Cargando…
Integrative Analysis of Epigenetic Modulation in Melanoma Cell Response to Decitabine: Clinical Implications
Decitabine, an epigenetic modifier that reactivates genes otherwise suppressed by DNA promoter methylation, is effective for some, but not all cancer patients, especially those with solid tumors. It is commonly recognized that to overcome resistance and improve outcome, treatment should be guided by...
Autores principales: | Halaban, Ruth, Krauthammer, Michael, Pelizzola, Mattia, Cheng, Elaine, Kovacs, Daniela, Sznol, Mario, Ariyan, Stephan, Narayan, Deepak, Bacchiocchi, Antonella, Molinaro, Annette, Kluger, Yuval, Deng, Min, Tran, Nam, Zhang, Wengeng, Picardo, Mauro, Enghild, Jan J. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2642998/ https://www.ncbi.nlm.nih.gov/pubmed/19234609 http://dx.doi.org/10.1371/journal.pone.0004563 |
Ejemplares similares
-
PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF(WT) melanoma cells
por: Halaban, Ruth, et al.
Publicado: (2010) -
Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032
por: Rubinstein, Jill C, et al.
Publicado: (2010) -
A novel anti-melanoma SRC-family kinase inhibitor
por: Halaban, Ruth, et al.
Publicado: (2019) -
Detecting copy number status and uncovering subclonal markers in heterogeneous tumor biopsies
por: Parisi, Fabio, et al.
Publicado: (2011) -
Integrated Analysis of Tumor Samples Sheds Light on Tumor
Heterogeneity
por: Parisi, Fabio, et al.
Publicado: (2012)